MSD ventures into fibroblast therapies with $1.9bn deal with Mestag – Pharmaceutical Technology
Mestag’s pipeline consists of antibody therapies based on fibroblast-immune interactions as a treatment for cancer and inflammatory diseases. Image credit: Sergiy Palamarchuk / Shutterstock. MSD